| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.RMED.2004.11.006 |
| P8608 | Fatcat ID | release_t6ve6nhocnhifmwh2ji2gea7zy |
| P698 | PubMed publication ID | 15878483 |
| P5875 | ResearchGate publication ID | 7863399 |
| P2093 | author name string | Agusti AG | |
| P433 | issue | 6 | |
| P304 | page(s) | 670-682 | |
| P577 | publication date | 2005-01-08 | |
| P1433 | published in | Respiratory Medicine | Q2659932 |
| P1476 | title | COPD, a multicomponent disease: implications for management | |
| P478 | volume | 99 |
| Q34945953 | A cohort study of the impact of tooth loss and periodontal disease on respiratory events among COPD subjects: modulatory role of systemic biomarkers of inflammation |
| Q33641025 | Absolute rather than relative income is a better socioeconomic predictor of chronic obstructive pulmonary disease in Swedish adults |
| Q37822219 | Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine |
| Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
| Q54549439 | An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. |
| Q35531955 | Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease |
| Q37115862 | Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences |
| Q41203086 | Bacterial vaccines in chronic obstructive pulmonary disease: effects on clinical outcomes and cytokine levels. |
| Q37012728 | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease |
| Q35637295 | COPD association and repeatability of blood biomarkers in the ECLIPSE cohort |
| Q40927408 | Cancer antigen-125 levels predict long-term mortality in chronic obstructive pulmonary disease. |
| Q34149510 | Characterisation of COPD heterogeneity in the ECLIPSE cohort |
| Q35993534 | Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries |
| Q37254911 | Creatine supplementation and physical training in patients with COPD: a double blind, placebo-controlled study |
| Q37890759 | Current controversies and future perspectives in chronic obstructive pulmonary disease |
| Q51599339 | Diffusion capacity of the lung for carbon monoxide - A potential marker of impaired gas exchange or of systemic deconditioning in chronic obstructive lung disease? |
| Q64930474 | Disease-Specific Comorbidity Clusters in COPD and Accelerated Aging. |
| Q58771036 | Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease |
| Q89566056 | Improving the Efficiency of Respiratory Drug Delivery: A Review of Current Treatment Trends and Future Strategies for Asthma and Chronic Obstructive Pulmonary Disease |
| Q40179319 | Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology |
| Q49704801 | Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. |
| Q28587857 | Lower extremity and carotid artery disease in COPD |
| Q35696088 | Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. |
| Q37352193 | Metabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary disease. |
| Q38041635 | Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1. |
| Q36742804 | Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena |
| Q34854354 | Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report |
| Q42751012 | Pharmacological profile of roflumilast |
| Q47551310 | Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease |
| Q24202545 | Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease |
| Q24234493 | Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease |
| Q24243560 | Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease |
| Q38621357 | Platelet distribution width as a prognostic factor in patients with COPD - pilot study |
| Q57494701 | Preview of highlighted presentations from the European Respiratory Society' clinical assembly |
| Q57955615 | Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease |
| Q24187999 | Pulmonary rehabilitation for chronic obstructive pulmonary disease |
| Q37277373 | RNAi Therapeutic Platforms for Lung Diseases |
| Q64270436 | Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD |
| Q46057464 | Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients |
| Q36293943 | Relationship between BODE index, quality of life and inflammatory cytokines in COPD patients |
| Q36585746 | Responsiveness of blood and sputum inflammatory cells in Japanese COPD patients, non-COPD smoking controls, and non-COPD nonsmoking controls. |
| Q40024513 | Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro |
| Q26770501 | Roflumilast: a review of its use in the treatment of COPD |
| Q36379352 | Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease |
| Q37319950 | Role of macrolide therapy in chronic obstructive pulmonary disease |
| Q43509713 | Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants |
| Q36993392 | Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease |
| Q51159286 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. |
| Q40254842 | Study Design and Interim Outcomes of Guangzhou Institute of Respiratory Disease COPD Biobank |
| Q36645461 | Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids |
| Q38006928 | Systemic inflammation and comorbidities in chronic obstructive pulmonary disease |
| Q42764765 | Systemic inflammation and progression of COPD. |
| Q36779343 | Tackling COPD: a multicomponent disease driven by inflammation |
| Q36956720 | Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease |
| Q26828971 | The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease |
| Q46185080 | The efficacy and safety of cilomilast in COPD. Forward |
| Q35574530 | Use of cluster analysis to describe desaturator phenotypes in COPD: correlations between pulmonary function tests and nocturnal oxygen desaturation |
| Q37242596 | Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study |
| Q57955632 | Validation of the i-BODE Index as a Predictor of hospitalization and Mortality in Patients with COPD Participating in Pulmonary Rehabilitation |
| Q58840477 | What the Journal Would Like to Publish on Chronic Obstructive Pulmonary Disease |
| Q36809938 | Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis |
| Q83113636 | ["Genes for mitochondria" in arterial hypertension and left ventricular hypertrophy] |
| Q82707757 | [Anxiety and COPD] |
| Q83401071 | [Clinical phenotypes of COPD] |
| Q84148874 | [Complexity in chronic obstructive pulmonary disease. Individualized treatment, new approaches, phenotypes and comorbidities] |
| Q79918388 | [Pathogenesis of chronic obstructive pulmonary disease] |
| Q83410651 | [Phosphodiesterase 4 inhibitors: a new pharmacologic group in the treatment of chronic inflammation of the airways] |
| Q80941596 | [Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study] |
Search more.